The melanoma field has seen an unprecedented set of clinical advances over the past
decade. Therapeutic efficacy for advanced or metastatic melanoma went from being one of …

The mitogen-activated protein kinase (MAPK) pathway plays a vital role in cellular
processes such as gene expression, cell proliferation, cell survival, and apoptosis. Also …

Neoadjuvant ipilimumab and nivolumab induces high pathologic response rates (pRRs) in
clinical stage III nodal melanoma, and pathologic response is strongly associated with …

Neoadjuvant ipilimumab plus nivolumab showed high pathologic response rates (pRRs) in
patients with macroscopic stage III melanoma in the phase 1b OpACIN (NCT02437279) and …

We concurrently examine the whole genome, transcriptome, methylome, and immune cell
infiltrates in baseline tumors from 77 patients with advanced cutaneous melanoma treated …

Outcomes for patients with melanoma have improved over the past decade as a result of the
development and FDA approval of immunotherapies targeting cytotoxic T lymphocyte …

Immune and targeted therapies achieve long-term survival in metastatic melanoma;
however, new treatment strategies are needed to improve patients' outcomes,. We report on …

Background Neoadjuvant ipilimumab plus nivolumab has yielded high response rates in
patients with macroscopic stage III melanoma. These response rates translated to high short …

Purpose: In the phase III CheckMate 238 study, adjuvant nivolumab significantly improved
recurrence-free survival (RFS) and distant metastasis-free survival versus ipilimumab in …

Hyperactivation of PI3K/AKT/mTOR and MAPK/MEK/ERK signaling pathways is commonly
observed in many cancers, including triple-negative breast cancer (TNBC) and melanoma …